Collaboration and License Agreements (Tables)

9 Months Ended

Dec. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Collaboration and License Agreements

The following table presents changes in the Company’s contract liabilities during the nine months ended December 31, 2021 (in thousands):

	Balance at March 31, 2021		Additions		Imputed Interest		Deductions		Balance at December 31, 2021
Contract liabilities:
Deferred revenue (1)	$	497,933	$	100,000	$	—	$	(96,520)	$	501,413
Cost share advance from Pfizer (2)	$	121,862	$	—	$	1,818	$	(68,654)	$	55,026

(1) Includes $100.6 million and $400.8 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of December 31, 2021. Includes $100.6 million and $397.4 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2021.

(2) Includes $55.0 million presented as current on the unaudited condensed consolidated balance sheet as of December 31, 2021. Includes $92.4 million and $29.4 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2021.